← Eichor
Condition: Chronic Myelogenous Leukemia In Chronic Phase Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Chronic Myelogenous Leukemia In Chronic Phase

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06817720Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, M
Phase 1/Phase 2 · 1 location(s) · Uma Borate · NCT06523556Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06757855Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Phase 2 · 11 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06409936Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Phase 2 · 4 location(s) · Theradex · NCT07033598Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chro
Phase N/A · 4 location(s) · Hikma Pharmaceuticals LLC · NCT05282108Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetocla
Phase 2/Phase 3 · 71 location(s) · Taiho Oncology, Inc. · NCT04256317Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1 · 1 location(s) · University of Chicago · NCT03326310IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
Phase 3 · 43 location(s) · ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · NCT06647862Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04260022Study to Evaluate the Safety and Tolerability of EP0042
Phase 1/Phase 2 · 6 location(s) · Ellipses Pharma · NCT04581512Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07071155Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogen
Phase 1/Phase 2 · 6 location(s) · Heinrich-Heine University, Duesseldorf · NCT05807932A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT05367700Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Phase 1 · 5 location(s) · Clinical Hub for Interventional Research (CHOIR) · NCT05636514MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06401603A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06566742Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.